Cell Surface Makers Market By Products (Flow Cytometry, Hematology Analyzers, Cell Imaging Systems, and Reagents and Kits), By Applications (Disease Diagnosis, and Research and Drug Discovery), and By Region - Trends, Analysis and Forecast till 2030

Cell Surface Makers Market accounted for USD 594.05 Million in 2020 and is estimated to be USD 1221.63 Million by 2030 and is anticipated to register a CAGR of 7.50%.

Cell surface markets are proteins expressed on the cells’ surface and often serve as markers of particular cell types. Cell surface markers are usually molecules or antigens inside the plasma membrane of the cell. These markers are the chief components in the categorization and identification of cells including macrophages, lymphocytes, tumor cells, monocytes, and other cells primarily related to immunology. Cell surface market analysis can allow simplification of disease identification and diagnosis, drug discovery, and sample preparation. This analysis can take place with different samples, including blood, bone marrow, lymph nodes, and other tissues.

Use of advanced techniques

The factors that drive the growth of the global cell surface market are advancement in healthcare technology and growing inclination towards minimizing healthcare expenditure by reducing the cost associated with diagnosis. The increasing utilization of in vitro diagnostics, the rising automation in laboratories, the reduction in the cost of diagnosis, and the requirement for lowering healthcare expenditures globally are amongst the chief factors stimulating the market for cell surface markers.

High demands for new antibodies

 In addition, the rise of new markets will lead to a high demand for new antibodies, therefore boosting the demand for the global cell surface markers market. Furthermore, the rising occurrence of chronic diseases such as autoimmune disorders and cancer, the simplification of analysis procedures, and the rising automation of solutions and technologies are also amongst the major factors augmenting the growth of the global market. On the other hand, the complications involved in the utilization of flow cytometers and the negligence in making huge investments for gaining access to cutting-edge models are amongst the chief factors impeding the growth of the global market for cell surface markers.  Moreover, it has an opportunity in personalized medicine, in which it can help the physician decide the most effective therapy to be used for the patient.

The cell surface makers market is segmented based on product, application, and region.

Based on product, the cell surface makers market is segmented into flow cytometry, hematology analyzers, and cell imaging systems, and reagents and kits. Flow Cytometer is the most widely used instrument due to availability of a variety of flow cytometers. Flow cytometers have proved to be efficacious in drug discovery as well as in research, which further fuels their demand. Based on application, the targeted global market is bifurcated into disease diagnosis, and research and drug discovery. Cell surface marker application in research and drug discovery is expected to dominate the target market as cell marker analysis is widely used by pharmaceutical manufacturers and researchers in their research and development process and in drug discovery.

Regional Insights:

Based on the region the cell surface makers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounts highest revenue share to the cell surface makers market due to growing demand for advanced medical technologies and increasing geriatric population. Asia Pacific cell surface makers market is projected to register a high CAGR over the forecast period owing to the growing trend of increasing number of life sciences research activities and government initiatives to boost the biotechnology and pharmaceutical industries in several Asian countries.                                    

Cell Surface Makers Market, By Product:

• Flow Cytometry
• Hematology Analyzers
• Cell Imaging Systems
• Reagents and Kits

Cell Surface Makers Market, By Application:

• Disease Diagnosis
• Research and Drug Discovery

Cell Surface Makers Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Cell Surface Makers Market, By Product
    • Middle East & Africa Cell Surface Makers Market, By Application
    • Middle East & Africa Cell Surface Makers Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Cell Surface Makers Market, By Product
    • Latin America Cell Surface Makers Market, By Application
    • Latin America Cell Surface Makers Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Cell Surface Makers Market, By Product
    • Asia Pacific Cell Surface Makers Market, By Application
    • Asia Pacific Cell Surface Makers Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Cell Surface Makers Market, By Product
    • Europe Cell Surface Makers Market, By Application
    • Europe Cell Surface Makers Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Cell Surface Makers Market, By Product
  • North America Cell Surface Makers Market, By Application
  • North America Cell Surface Makers Market, By Country
    • U.S.
    • Canada

The key players operating the cell surface makers market involves Thermo Fisher Scientific, QIAGEN N.V., Becton, Dickinson and Company, F. Hoffman-La Roche, Bio-Rad Laboratories, Danaher Corporation, Abcam, GenScript , BioLegend, Cell Signaling Technology (US), Merck KGaA, and Bio-Techne . In January 2019, BD announced the commercial availability of their new kits which is specially designed for the identification and quantification of the information of the cells.  In May 2019, GE Healthcare announced the launch of their Cryochain software that is specially designed for the cell therapy. The main aim is to reduce development process and therapy. On Sep 7, year 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business of Becton, Dickinson and Company. This will be integrated into the Life Sciences Solutions segment of Thermo Fisher.

• Thermo Fisher Scientific
• QIAGEN N.V.
• Becton, Dickinson and Company
• F. Hoffman-La Roche
• Bio-Rad Laboratories
• Danaher Corporation
• Abcam
• GenScript
• BioLegend
• Cell Signaling Technology (US)
• Merck KGaA
• Bio-Techne